Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/35421
標題: 紐西蘭佳葉龍茶對四氯化碳誘導大鼠肝損傷之護肝功能評估
Hepatoprotective Effect of New Zealand GABA Tea on Carbon Tetrachloride-Induced Liver Injury in Rats
作者: 陳品璇
Chen, Pin-Husan
關鍵字: GABA tea
佳葉龍茶
γ-amino butyric acid
Carbon tetrachloride
Hepatoprotective effect
γ-胺基丁酸
四氯化碳
護肝
出版社: 生物產業機電工程學系所
引用: 戶田剛太郎著,彤雲譯。1999。肝臟病常識與防治。台北:武陵出版有限公司。 王雪芳。2006。台灣佳葉龍茶主要化學成分及其生理功效之研究。博士論文。台中 : 國立中興大學食品暨應用生物科技學系。 王聖心。2000。何首烏萃取物對小白鼠體內抗氧化酵素活性之影響。碩士論文。台中:靜宜大學食品營養學系。 甘子能。1984。茶葉化學入門。桃園:台灣省茶葉改良場。 白松、林向陽、阮榕生、鄭丹丹、劉玉環、何承云。2005。γ-胺基丁酸的分布與製備。現代食品科技。21: 202-205。 田甜。2006。紅麴菌魚黃豆機質上之生長及monacolin k 之產生。碩士論文。台北:大同大學生物工程研究所。 江天惠。2001。吸菸與粥狀動脈硬化危險因子相關性之探討。碩士論文。台中:中山醫學院營養科學研究所。 行政院農業委員會。農業統計年報。行政院農業委員會編印。 行政院衛生署。2003。健康食品之護肝功能評估方法(針對化學性肝損傷)。 行政院衛生署統計室。2009。台灣地區死因統計結果摘要。 吳玉霞。2001。飼料維他命E含量對馬拉巴石斑稚魚成長體組成與健康指標的影響。碩士論文。高雄:國立中山大學海洋生物研究所。 吳亮宜、孫璐西。2004。茶與健康。科學發展。384: 18-23。 吳昭慧。2007。香椿萃取物對大鼠肝腫瘤、肝癌細胞及致變異抑制作用之研究。碩士論文。台中:國立中興大學獸醫病理學研究所。 宋瑞樓、陳定信、廖運範。2006。肝炎肝硬化與肝癌。橘井文化事業股份有限公司。 李名袁。2007。製造高品質佳葉龍茶之最適操作條件。碩士論文。台中 : 國立中興大學生物產業機電工程學系。 李敏雄、張如華。1993。佳葉龍茶及其降血壓作用。食品工業。25: 38-44。 阮逸明。1991。茶葉可溶分及主要化學成分萃取之研究。台灣茶葉研究彙報。10: 89-108。 阮逸明。1995。茶葉的保健功效。茶葉技術推廣手冊-製茶篇。臺灣省茶葉改良廠編印。107-118。 林千筑。2010。佳葉龍茶對小鼠免疫調節功能之研究。碩士論文。台中:國立中興大學生物產業機電工程學系。 林木連、陳澤珊。2004。佳葉龍茶的由來及現行發展概況。興大農業。49: 1-2。 林木連、蔡右任、張清寬、陳國任、楊盛勳、陳英玲、賴正南、陳玄、張如華。2003。茶葉的營養價值與保健功效。台灣的茶葉。台北:遠足文化事業股份有限公司。172-179。 林伊凡。2009。水飛薊素對人類肝癌細胞粒線體呼吸及存活影響之研究。碩士論文。台北:國立陽明大學醫學院藥理學研究所。 林欣榜。2002。植物多酚類的機能性及應用。食品工業。34: 39-47。 林慧貞。2007。大蒜精油與蜆水萃取液對四氯化碳誘導大鼠肝損傷之影響。碩士論文。台北:國立臺灣大學生農學院食品科技研究所。 姚國坤、王存禮、程啟坤。1994。中國茶文化。台北:洪葉文化。 茶之藝文─茶文化。台灣茶訊。http://www.tea520.com.tw/ 區少梅、蔡永生、張如華。1988。包種茶酚類化合物分析方法比較評估。台灣茶葉研究彙報。7: 43-61。 區少梅。2002。吃GABA降血壓。台北 : 元氣齋出版社。 張志純。1983。茶葉的科學研究。台北:徐氏基金會出版。 張富偉。2008。台灣烏龍茶產業文化研究。碩士論文。台南:國立台南大學台灣文化研究所。 張暉、姚惠源、姜元榮。2006。食品原料中GABA的富集研究發展。現代食品科技。22: 196-198。 陳玉舜、區少梅。1995。包裝與貯藏條件對包種茶主要化學成分變化之影響。中國農業化學會誌。33: 647-664。 陳克紹。1992。佳芭茶抗高血壓作用之研究。中華藥學雜誌。44: 495-500。 陳清泉。1999。兒茶素之抗癌及抗腫瘤效應。食品工業。31:1-15。 陳清泉。2001。茶葉之兒茶素的機能及應用。食品市場資訊。90: 16-23。 陳惠英、顏國欽。1998。自由基、抗氧化防禦與人體健康。中華民國營養學會雜誌。23: 105-121。 陳雅琳。2004。複方五味子芝蔴萃取物對於四氯化碳誘導大白鼠。碩士論文。台北:台北醫學大學保健營養學系。 陳筱慧。2006。利用HPLC方法檢測發芽種子、發芽玄米、加碼茶、以及市售GABA膠囊中GABA含量。碩士論文。台中:國立中興大學食品暨應用生物科技學系。 陳蓓芳。1990。冷凍乾燥產品氧化作用的探討及其防止。台中:國立中興大學食品科學系碩士論文。 曾道一、賈宜琛。2003。食品科學導論。台北 : 新文京開發出版社股分有限公司。 游明謙、李誌雄、賴呈委、江宜平、王櫻諭、許清祥。2003。保肝中藥抽取物對半乳糖胺誘發急性肝細胞損傷之療效評估。中醫藥雜誌。14 (2): 99-108。 馮光良。2009。茶葉抗氧化功效分析及佳葉龍茶護肝功能研究。碩士論文。台中:國立中興大學生物產業機電工程系。 馮鑑淮、沈明來。1990。茶樹育種提早選種指標的研究Ⅱ. 品種芽葉農藝性狀與產量及綠茶兼包種茶以及紅茶品質之關係。臺灣茶業研究彙報。9: 7-20。 黃亞輝、鄭紅發、曾貞、劉霞林。2001。金白龍茶(GABARON)的研製及臨床試驗。茶葉通訊。4: 3-5。 楊盛勳、賴正男。1997。台灣茶葉起源與特色。財團法人台北市七星農田水利研究發展基金會出版。 萬璽。2003。喝綠茶,健康又養生。台北:培貞文化企業有限公司。 詹惠鈞。2003。改良式發酵普洱茶官能品質之影響。碩士論文。台中 : 國立中興大學食品科學系。 廖慶樑。2000。台灣之茶文化與科學(上)。茶葉專訊。33。 劉恩慧。2006。綠茶冷水及熱水萃之品質評估及抗氧化性質。碩士論文。台中 :國立中興大學食品暨應用生物科技學系。 劉新裕。2008。台灣北、中及南部三地區中草藥種植可行性評估。中醫藥年報。26: 463-510。 劉瑞華、葉明憲。2003。全球化與本土化的交織:台灣茶產業的長期變遷。思與言。41。 蔡永生、阮逸明、張如華。1995。佳葉龍茶之研製。農特產品加工研討會專刊。162-178。 蔡永生、區少梅、王雪芳。2004。佳葉龍茶之保健功效。興大農業。49: 3-8。 蔡永生、區少梅、張如華。1991。包種茶茶湯水色 – 包種茶茶湯水色與酚類化合物之關係。台灣省茶業改良場研究彙報。10: 65。 蔡永生、區少梅。2004。佳葉龍茶之保健功效。興大農業。49: 15-18。 蔡永生。2004。佳葉龍茶之製造。興大農業。49: 3-8。 蔡哲雄、陳昭姿。2001。對抗癌症系列(三)肝病三部曲。天下生活出版股份有限公司。 鄭祖耀、郭姿均。2010。抽血說出「肝」心聲。好心肝會刊。51。 賴俊銘。1992。包種茶官能品質分析及包裝改進之研究。博士論文。台中 : 國立中興大學食品暨應用生物科技學系。 戴宗和。2009。奈米黃金、奈米黃金與樟芝固態萃取液對大鼠化學性肝損傷功效之研究。碩士論文。台南:南台科技大學生物科技研究所。 聯合國農糧組織。http://www.fao.org/ 謝俊生。1991。台灣金線連抑制肝癌細胞生長抗氧化機制的探討。碩士論文。台中:中國醫藥學院醫學研究所。 謝博生、林肇堂、楊泮池、江福田。1992。臨床內科學診斷篇(上篇)。台北:金名圖書有限公司。 謝馥如。2002。由氧化壓力探討化學性肝損傷之機制。食品工業。34: 16-29。 顏志泰。2007。巴西洋菇食療方對四氯化碳誘導大鼠氧化性肝損傷之護肝功效評估。碩士論文。台北:國立台灣大學生物資源暨農學院食品科技研究所。 譚健民。1999。肝功能異常時該怎麼辦?台北:生智文化事業有限公司。 大森正司、矢野とし子、岡本順子、津志田藤二郎、村井敏信、樋口満。1987。嫌気処理緑茶(ギャバロン茶)による高血圧自然発症ラットの血圧上昇抑制作用。農化。61: 1449-51。 大森正司。1992。佳葉龍茶健康法-高血壓與二日宿醉預防特效(日文)。東京:健友館出版。 大森正司。1995。茶を科学するそのルーツから薬効まで。日本家政学会誌。46: 703-709。 松村敬一郎。1991。茶の科学。東京:朝倉書店。 津志田藤二郎。1986。 血壓降下作用を強化した茶の製造。茶。39: 1-6。 澤井祐典、許斐健一、小高保喜、吉冨均、山口優一、深山大介、竹内敦子。1999。嫌気-好気交互処理による茶葉のγ-アミノ酪酸量の増加。Nippon Shokuhin Kagaku Kogaku Kaishi。46: 462-466。 Ames, B. N. 1990. Endogenous DNA damage as related to cancer and aging. Mutat Res. 214: 41-46. Arroyo V. 2002. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol. 1:72-9. Balentine, D. A., S. A. Wiseman and L. C. Bouwens. 1997. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 37: 693-704. Benzie, I. F. F. 2000. Evolution of antioxidant defence mechanisms. Eur. J. Nutr. 39: 53-61. Cadenas. 1997. Basic mechanisms of antioxidant activity. Biofactors. 6: 391-397. Cameron, G. R. and W. A. E. Karunaratne. 1936. Carbon tetrachloride cirrhosis in relation to liver regeneration. J.Pathol. Bacteriol. 42: 1-21. Chew, G. T. and G. F. Watts. 2004. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ‘recoupling hypothesis’. Oxford Journals. Medicine. 97: 537-548. De la Iglesia, F., J. M. Sturgess and G. Feuer. 1982. New approaches for assessment of hepatotoxicity by means of quantitative functional-morphological interrelationship in toxicity of liver. Eds. G. L. Plaa and W. R. Hewitt. New York: Raven Press. Clarendon Press. Oxford. 23-28. Deisseroth, A. and A. L. Dounce. 1970. Catalase: Physicial and Chemical Properties, Mechanism of Catalysis, and Physiological Role, Physiol. Rev. 50: 319-375. Gey, K. F., P. Puska, P. Jordan and U. K. Moser. 1991. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am. J. Clin. Nutr. 53: 326S-334S. Gillery, P., J. C. Monboisse, F. X. and J. P. Maquart Borel. 1988. Glycation of proteins as a source of superoxide. Diabete Metab. 14: 25-30. Giugliano, D., A. Ceriello and G. Paolisso. 1995. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism. 144: 363-368. Gomez, R. and H. M. T. Barros. 2000. Ethopharmacology of the antidepressant effect of clonazepam in diabetic rats. Pharmacology Biochemistry and Behavior. 66: 329-335. Halliwell, B., M. A. Murcia, S. Chirico and O. I. Aruoma. 1995. Free radicals and antioxidants in food and in vivo:what they do and how they work. Crit Rev Food Sci. Nutr. 35: 7-20. Hasanloo, T., R. A. Khavari-Nejad, E. Majidi, and M. R. Shams Ardakani. 2008. Flavonolignan Production in Cell Suspension Culture of Silybum marianum. Pharmaceutical Biology. 46: 876-882. Heinecke, J. W. 1998. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 141: 1-15. Hunt, J. V., C. C. Smith and S. P. Wolff. 1990. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 39: 1420-24. Jacob, R. A. 1995. The integrate antioxidant system. Nutr Res. 15: 755-766. Jaeschke, H. 2000. Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol. 15: 718-724. Kehrer, J. P. 1993. Free radicals as mediators of tissue injury and disease. Crit. Rev. Toxicol. 23: 21-48. Kim, S. G., S. Y. Nam, H. C. Chung, S. Y. Hong and K. H. Jung. 1995. Enhanced effectiveness of dimethy1-4, 4’-dimethoxy-5,6,5’6,- dimethylene dioxylbipheny1-2,2’-dicarboxylate in combination with garlic oil against experimental hepatic injury in rats and mice. J. Pharm. Pharmacol. 47: 678-682. Knodell, R. G., K. G. Ishak, W. C. Black, T. S. Chen, R. Craig, N. Kaplowitz, T. W. Kiernan and J. Wollman. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1: 431-435. Lin, Z., H. Saito, M. Omori, T. Inomata, M. Kato, Y. Sawai, S. Fukatu and K. Hakamata. 2000. Effect of gabaron tea on the blood pressure and kidney function of rats loaded with saline. Nippon Kaseigaku Kaishi. 51: 265-271. Liu, S. L., S. D. Esposti, T. Yao, A. M. Diehl and M. A. Zern. 1995. Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology. 22:1474-81. Luper, S. 1998. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 3: 410-421. Meloun, M., D. Burkoňová, T. Syrový and A. Vrána. 2003. Thermodynamic dissociation constants of silychristin, silybin, silydianin and mycophenolate by the regression analysis of spectrophotometric data. Anal. Chim. Acta. 486: 125-141. Mergl, Z., Z. Acs and G. B. Makara. 1995. Growth hormone secretion and activation of cyclic AMP by growth hormone releasing hormone and gamma-aminobutyric acid in the neonatal rat pituitary. Life Science. 56: 579-585. Millin, D. J. and D. W. Rustidge. 1967. Tea manufacture. Process Biochemistry. 6: 9-13. Moncada, S., R. J. Gryglewski, S. Bunting and J. R. Vane. 1976. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 12: 715-737. Moss, H. B., J. K. Yao, M. Buens, J. Maddock and R. E. Tarter. 1990. Plasma GABA-like activity in response to ethanol challenge in men at high risk for alcoholism. Biological Psychiatry. 27: 617-625. Mourelle M., Franco M. T. 1991. Erythrocyte defects precede the onset of CCl4-induced liver cirrhosis. Protection by silymarin. Life Sci. 4: 1083-90. Munro, J. M and R. S. Cotran. 1988. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 58: 249-261. Murase, T., A. Nagasawa, J. Suzuki, T. Hase and I. Tokimitzu. 2002. Beneficial effects of tea catechins on diet-induced obesity: Stimulation of lipicatabolism in the liver. Int. J. Obes. Relat. Metab. Disord. 9: 3-8. Murck, H., I. A. Antonijevic, T. Schier, R. M. Frieboes, J. Barthelmes, and A. Steiger. 1999. Aging does not affect the sleep endocrine response to total sleep deprivation in humans. Neurobiology of Aging. 20: 665-668. Muriel P., Mourelle M. 1990. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Applied Toxicol. 10: 275-279. Nishida, K., Y. Ohta and I. Ishiguro. 1998. Preventive effect of γ-glutamylcysteinylethyl ester on carbon tetrachloride-induced hepatic triglyceride accumulation in mice. Toxicol. Lett. 95: 141-146. Packer L. 1992. Interactions among antioxidants in health and disease: vitamin E and its redox cycle. Proc Soc Exp Biol Med. 200: 271-276. Paolisso, G., A. Amore, C. Volpe, V. Balbi and F. Saccomanno. 1994. Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients. Metabolism. 43: 1426-29. Popper, H. 1970. Hepattic fibrosis, correlation of biochemical and morphologic investigation. Am. J. Med. 49: 707. Pradhan, S. C. and C. Girish. 2006. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 124: 491-504. Quaglia, M. G., E. Bossu, E. Donati, G. Mazzanti and A. Brandt. 1999. Determination of silymarine in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J Pharm Biomed Anal. 19: 435-442. Rikans L. E. and K. R. Hornbrook. 1997. Lipid peroxidation, antioxidant protection and aging. Biochim Biophys Acta. 1362: 116-127. Robinson, C. H., M. R. Lawler, W. L. Chenoweth and A. E. Garwick. 1990. Normal and therapeutic nutrition: Diet in disturbance of liver, gallbladder, and pancreas. New York: Macmillan Publishing Co.17:458-469. Rossetti, V. and A. Lombard. 1996. Determination of glutamate decarboxylase by high-performance liquid chromatography. J. Chromatography B: Biomedical Sciences and Applications. 681: 63-67. Rothuizen, J., Y. D. Kok, A. Slob and J. A. Mol. 1996. GABAergic inhibition of the pituitary release of adrenocorticotropin and amelanotropin is impaired in dogs with hepatic encephalopathy. Domestic. Animal Endocrinology. 13: 59-68. Ruwart, M. J., K. F. Wilkinson, B. D. Rush. 1989. The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology. 10: 801-806. Sachan, D. S. and W. L. Dodson. 1992. Effects of L-carnitine onfcarbon tetrachloride-induced changes in serum and liver lipids and acylcarnitines. J. Environ. Pathol. Toxicol. Oncol. 11: 125-129. Saller, R., R. Meier and R. Brignoli. 2001. The use of silymarin in the treatment of liver disease. Drug. 6: 2035-63. Sanderson, G. W. 1972. The chemistry of tea and tea manufacturing. Recent Advances in Phytochemistry. V. C. Runeckles and T. C. Tso Ed. 5: 247-316. Shelp, B. J., A. W. Bown and M. D. McLean. 1999. Metabolism and functions of gamma-aminobutyric acid. Trends in Plant Science. 4: 446-452. Shiah, I. S., H. A. Robertson, R. W. Lam, L. N. Yatham, E. M. Tam and A. P. Zis. 1999. Growth hormone response to baclofen in patients with seasonal affective disorder: effects of light therapy. Psychoneuroendocrinology. 24: 143-153. Shimada, K., K. Fujikawa, K. Yahara and T. Nakamura. 1992. Antioxidative properties of xanthan on the autoxidation of soybean oil in cyclodextrin emulsion. J. Agric. Food Chem. 40: 945-948. Sipes, I. G., A. E. El Sisi, W. W. Simm, S. A. Mobley and D. L. Earnest. 1989. Role of reactive oxygen species secreted by activated Kupffer cells in the potentiation of carbon tetrachloride hepatotoxicity by hypervitaminosis A. Cells of the Hepatic Sinusoid. 2: 376-379. Spector, A., G. M. Wang, R. R. Wang, W. C. Li and N. J. Kleiman. 1995. A brief photochemically induced oxidative insult causes irreversible lens damage and cataract. II. Mechanism of action. Exp Eye Res. 60: 483-493. Stahelin, H. B., K. F. Gey, M. Eichholzer, E. Ludin, F. Bernasconi, J. Thurneysen and G. Brubacher. 1991. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow-up of the prospective basal study. Am. J. Epidemiol. 133: 766-775. Sturgill, M. G. and G. H. Lambert. 1997. Xenobiotic-induced hepatotoxity: mechanism of liver injury and methods of monitoring hepatic function. Clin Chem. 43: 1512-26. Tada S., N. Nakamoto, K. Kameyama, S. Tsunematsu, N. Kumagai, H. Saito and H. Ishii. 2003. Clinical usefulness of edaravone for acute liver injury. J. Gastroenterol. Hepatol. 18: 851-857. Takahashi, H., M. Tiba and M. Iino. 1955. The effect of GABA on blood pressure, Jpn. J. Physiol. 5: 334-341. Tamayo, R. P. 1983. Is cirrhosis of the liver experimentally produced by CCl4 an adequste model of human cirrhosis? Hepatology. 3:112-120. Terada, S., Y. Maeda, T. Masui, Y. Suzuki and K. Ina. 1987. Comparison of caffeine and catechins components in infusion of various tea (green, oolong and black tea) and tea drinks. Nippon Shokuhin Kogyo Gakkaishi. 34: 20-27. Ueno, H. 2000. Enzymatic and structural aspects on glutamate decarboxylase. J. Molecular Catalysis B: Enzymatic. 10: 67-79. US Food and Drug Administration, C. f. D. E. a. R., USFDA, US Department of Health and Human Services. 2005. Guidance for Industry, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Wang, H. F., Y. S. Tsai, M. L. Lin and A. S. Ou. 2006. Comparison of bioactive components in GABA tea and green tea produced in Taiwan. Food Chemistry. 96: 648-653. Wegeliu, K., T. Halonen and E. R. Korpi. 1993. Gamma-viny GABA decreases voluntary alcohol consumption in alcohol-preferring rats. Pharmacol. Toxicol. 73:150-152. Wong, C. K., V. E. C. Ooi and P. O. Ang. 2000. Protective effects of seaweeds against liver injury caused by carbon tetrachloride in rats. Chemosphere.41: 173-176. Zafari A. M., D..G. Harrison and K. K. Griendling. 1999. Vascular oxidant stress and nitric oxide bioactivity. Panza JA, Cannon RO III (eds): Endothelium, Nitric Oxide, and Atherosclerosis. Armonk NY, Futura Publishing Co, Inc. 133-144. Zamocky, M. and F. Koller. 1999. Understanding the Structure and Function of Catalase: Clues from Molecular Evolution and In Vitro Mutagenesis, Prog. Biophys. Mol. Biol. 72:19-66. Zuo, Y., H. Chen and Y. Deng. 2002. Simultaneous deterimination ofcatechins, caffeine and gallic acids in green, oolong, black and pu-erh teas using HPLC with a photodiode array detector. Talanta. 57: 307-316.
摘要: 已知佳葉龍茶是一種富含γ-胺基丁酸(GABA)的保健茶品,為了解是否具有護肝功效,本研究使用Eterna Holdings Limited產製之紐西蘭佳葉龍茶,分析冷凍乾燥前後之成分變化,並依護肝功能(針對化學性肝損傷)評估方法,進行四氯化碳(CCl4)誘導慢性肝損傷之大鼠肝功效評估。成分分析結果顯示,紐西蘭佳葉龍茶經冷凍乾燥後,總兒茶素、總多元酚及個別兒茶素等成分含量減少,但GABA含量則無差異。護肝動物模式試驗,以雄性大鼠(SD品系),分為正常對照組(Control)、低劑量紐西蘭佳葉龍茶處理組(1X Gtw)及高劑量組(5X Gtw)及200 mg/kg Silymarin正對照組與20% CCl4負對照組等5組。第0週時僅餵食紐西蘭佳葉龍茶及silymarin做預先保護1週後開始餵食CCl4,每週測量大鼠體重及飼料攝取量,實驗期共八週。結果顯示,餵食紐西蘭佳葉龍茶與silymarin具有減輕CCl4引起的肝重量上升及肝腫大。CCl4會對肝臟造成損傷,使AST、ALT值上升,1X Gtw、5X Gtw與Silymarin組皆於第八週有效的降低血清中AST與ALT值。肝臟切片組織病理結果顯示,Silymarin、1X Gtw與5X Gtw組均可減少因CCl4引起肝細胞空泡化及壞死,病理積分均有顯著性下降,但對肝纖維化則無影響。抗氧化能力方面,因個體差異過大,各組間無顯著性差異。綜合以上實驗結果,紐西蘭佳葉龍茶經冷凍乾燥不影響GABA含量。紐西蘭佳葉龍茶具有降低CCl4 對肝臟造成血清中AST與ALT 值上升,及肝細胞空泡化及壞死等化學性肝損傷作用。
GABA tea is a traditional tea and is known in rich with γ-amino butyric acid (GABA). In order to evaluate the hepatoprotection of New Zealand GABA tea on the effects of chronic liver injury induced by carbon tetrachloride in rats, the New Zealand GABA tea was produced by Eterna Holdings Limited, and was analyzed the change of compositions before and after lyophilizing. Results exhibited that the contents of total catechins, total polyphenols and individual catechins of New Zealand GABA tea were reduced, but no significant change in the GABA contents after lyophilizing. Male rats (SD strain) were divided into five groups: normal control group (Control), New Zealand GABA tea of low-dose treatment group (1X Gtw), high-dose treatment group (5X Gtw) and 200 mg/kg Silymarin positive control group and 20% CCl4 as negative control group. On the 0th week in the tea samples and silymarin fed one week for protection, and then fed with CCl4, at 1st week. Rats were weekly recorded the body weight and feed intake for 8 weeks. The results showed that fed with New Zealand GABA tea and silymarin, had lessened the increase in liver weight that caused by CCl4. CCl4 caused liver damage, and increases the serum AST and ALT. Treatment with 1X Gtw, 5X Gtw and Silymarin showed effectively reducing in the parameters of AST and ALT. In additional, histopathological findings show that Silymarin, 1X Gtw, 5X Gtw group can reduce the CCl4-induced liver cell vacuolization and necrosis, as well as the histopathologic scores decrease. However, no effect is noted in the hepatic fibrosis in each group. Furthermore, the antioxidant activities had no significant difference between the control and treated groups. In conclusion, no significant change of New Zealand GABA tea in the GABA contents after lyophilizing. Animal experiments also showed that New Zealand GABA tea can reduce the liver damage caused by CCl4 on serum AST and ALT values, and attenuate the vacuolization and necrosis in the chemical-induced liver injury in rats.
URI: http://hdl.handle.net/11455/35421
其他識別: U0005-2107201116453500
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-2107201116453500
Appears in Collections:生物產業機電工程學系

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.